Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Non-Inferiority, Randomized Phase III Clinical Study Comparing Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in the Treatment of Advanced HER2-Positive Breast Cancer

NCT07615751 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07615751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07615751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Non-Inferiority, Randomized Phase III Clinical Study Comparing Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in the Treatment of Advanced HER2-Positive Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
February 12, 2025
Completion date
December 30, 2029
Enrollment
502 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer